- Home
- OCUP vs KPLT Comparison
OCUP vs KPLT Comparison
Compare OCUP & KPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUP
- KPLT
- Stock Information
- Founded
- OCUP 2018
- KPLT 2012
- Country
- OCUP United States
- KPLT United States
- Employees
- OCUP N/A
- KPLT N/A
- Industry
- OCUP Biotechnology: Pharmaceutical Preparations
- KPLT Diversified Commercial Services
- Sector
- OCUP Health Care
- KPLT Consumer Discretionary
- Exchange
- OCUP Nasdaq
- KPLT Nasdaq
- Market Cap
- OCUP 53.1M
- KPLT 49.2M
- IPO Year
- OCUP N/A
- KPLT N/A
- Fundamental
- Price
- OCUP $1.25
- KPLT $9.42
- Analyst Decision
- OCUP Strong Buy
- KPLT Hold
- Analyst Count
- OCUP 3
- KPLT 1
- Target Price
- OCUP $18.67
- KPLT $15.00
- AVG Volume (30 Days)
- OCUP 92.2K
- KPLT 22.9K
- Earning Date
- OCUP 11-11-2024
- KPLT 11-06-2024
- Dividend Yield
- OCUP N/A
- KPLT N/A
- EPS Growth
- OCUP N/A
- KPLT N/A
- EPS
- OCUP N/A
- KPLT N/A
- Revenue
- OCUP $16,449,000.00
- KPLT $236,293,000.00
- Revenue This Year
- OCUP N/A
- KPLT $14.79
- Revenue Next Year
- OCUP $258.69
- KPLT $12.23
- P/E Ratio
- OCUP N/A
- KPLT N/A
- Revenue Growth
- OCUP N/A
- KPLT 14.82
- 52 Week Low
- OCUP $1.15
- KPLT $8.26
- 52 Week High
- OCUP $3.40
- KPLT $23.54
- Technical
- Relative Strength Index (RSI)
- OCUP 44.19
- KPLT 35.84
- Support Level
- OCUP $1.24
- KPLT $9.36
- Resistance Level
- OCUP $1.39
- KPLT $9.89
- Average True Range (ATR)
- OCUP 0.07
- KPLT 0.41
- MACD
- OCUP -0.00
- KPLT 0.06
- Stochastic Oscillator
- OCUP 22.22
- KPLT 11.85
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc is a technology driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an E-Commerce focused FinTech company offering an innovative lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.